These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9014295)

  • 1. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly.
    Evans TG; Judd ME; Dowell T; Poe S; Daynes RA; Araneo BA
    Vaccine; 1996 Nov; 14(16):1531-7. PubMed ID: 9014295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DHEAS as an effective vaccine adjuvant in elderly humans. Proof-of-principle studies.
    Araneo B; Dowell T; Woods ML; Daynes R; Judd M; Evans T
    Ann N Y Acad Sci; 1995 Dec; 774():232-48. PubMed ID: 8597462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of DHEAS on influenza vaccination in aging adults.
    Degelau J; Guay D; Hallgren H
    J Am Geriatr Soc; 1997 Jun; 45(6):747-51. PubMed ID: 9180672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes.
    Kroon FP; van Dissel JT; de Jong JC; van Furth R
    AIDS; 1994 Apr; 8(4):469-76. PubMed ID: 7912086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects.
    Danenberg HD; Ben-Yehuda A; Zakay-Rones Z; Gross DJ; Friedman G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2911-4. PubMed ID: 9284718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial.
    Halperin SA; Smith B; Nolan C; Shay J; Kralovec J
    CMAJ; 2003 Jul; 169(2):111-7. PubMed ID: 12874157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.
    Somani J; Lonial S; Rosenthal H; Resnick S; Kakhniashvili I; Waller EK
    Vaccine; 2002 Dec; 21(3-4):221-30. PubMed ID: 12450697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly.
    Ben-Yehuda A; Danenberg HD; Zakay-Rones Z; Gross DJ; Friedman G
    Mech Ageing Dev; 1998 May; 102(2-3):299-306. PubMed ID: 9720660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
    McNeil SA; Noya F; Dionne M; Predy G; Meekison W; Ojah C; Ferro S; Mills EL; Langley JM; Halperin SA
    Vaccine; 2007 Apr; 25(17):3464-74. PubMed ID: 17270320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines.
    Nagai T; Suzuki Y; Kiyohara H; Susa E; Kato T; Nagamine T; Hagiwara Y; Tamura S; Yabe T; Aizawa C; Yamada H
    Vaccine; 2001 Sep; 19(32):4824-34. PubMed ID: 11535335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levamisole supplementation on tetanus vaccination response rates in haemodialysis patients: a randomized double-blind placebo-controlled trial.
    Fallahzadeh MK; Sajjadi S; Singh N; Khajeh M; Sagheb MM
    Nephrology (Carlton); 2014 Jan; 19(1):27-31. PubMed ID: 24341659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
    Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
    Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic response to a single dose of tetanus toxoid in older people.
    Shohat T; Marva E; Sivan Y; Lerman I; Mates A; Cohen A
    J Am Geriatr Soc; 2000 Aug; 48(8):949-51. PubMed ID: 10968300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.
    Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
    Vaccine; 2010 Oct; 28(43):6989-96. PubMed ID: 20728523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.